Belite Bio (BLTE) Net Cash Flow (2020 - 2025)
Belite Bio (BLTE) posted quarterly Net Cash Flow of $196.0 million for Q4 2025, up 2039.73% year-over-year from $9.2 million in Q4 2024, and up 2039.73% quarter-over-quarter from $9.2 million in Q4 2024.
Powered by 
Analysis
Belite Bio (BLTE) Net Cash Flow (2020 - 2025) Analysis & Trends
Belite Bio's Net Cash Flow history runs 2 years deep, the most recent figure standing at $196.0 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 2039.73% year-over-year to $196.0 million; the TTM figure through Mar 2026 stood at $196.0 million (up 2039.73% YoY), while the FY2025 annual figure was $321.1 million, up 671.31% from the prior year.
- Net Cash Flow for Q4 2025 stood at $196.0 million, up from $9.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $196.0 million in Q4 2025, with the low at $9.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Belite Bio | 6.44 Bn | 6.44 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 196.00 Mn |
| Dec 31, 2024 | 9.16 Mn |
| Dec 31, 2022 | -11.85 Mn |
| Dec 31, 2021 | -8.11 Mn |
| Dec 31, 2020 | -4.46 Mn |